Clinical Trial Update: Effect of the SCL16A11 Risk Haplotype on Treatments to Prevent Type 2 Diabetes [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating how the SCL16A11 risk haplotype influences treatments aimed at preventing type 2 diabetes in individuals with prediabetes; the study ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prediabetes

Snippet

Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Conditions: PreDiabetes | Phase 2 | Status: COMPLETED